WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 464995

CAS#: unknown

Description: Carboplatin-d4 is intended for use as an internal standard for the quantification of carboplatin by GC- or LC-MS. Carboplatin is a platinum-containing DNA-crosslinking agent. It induces the formation of DNA interstrand crosslinks and DNA-protein crosslinks when used at concentrations of 200 and 300 µM. It inhibits the proliferation of GLC-4 small cell lung carcinoma and A2780 and SKOV3 ovarian cancer cells (IC50s = 22.7, 0.5, and 10.2 µM, respectively). Carboplatin reduces tumor growth in an ADJ/PC6 murine plasmacytoma model (ED90 = 0.6 mg/kg, i.p.). Formulations containing carboplatin have been used in the treatment of ovarian cancer.

Chemical Structure

CAS# unknown

Theoretical Analysis

MedKoo Cat#: 464995
Name: Carboplatin-d4
CAS#: unknown
Chemical Formula: C6H8D4N2O4Pt
Exact Mass: 375.0696
Molecular Weight: 375.2804
Elemental Analysis: C, 19.20; H, 4.30; N, 7.46; O, 17.05; Pt, 51.98

Price and Availability

Size Price Availability Quantity
1.0mg USD 360.0 2 Weeks
Bulk inquiry

Synonym: Carboplatin-d4; Carboplatin d4; CDDCA-d4; CDDCA d4; CBDCA-d4; CBDCA d4; cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)-d4;

IUPAC/Chemical Name: N/A


InChi Code: InChI=1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2/i2D2,3D2;;;

SMILES Code: O=C(C1(C([O-]2)=O)C([2H])(CC1([2H])[2H])[2H])[O-][Pt+2]2([NH3])[NH3]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 375.2804 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Friedrich M, Friedrich D, Kraft C, Rogmans C. Multimodal Treatment of Primary Advanced Ovarian Cancer. Anticancer Res. 2021 Jul;41(7):3253-3260. doi: 10.21873/anticanres.15111. Epub 2021 Jul 5. PMID: 34230119.

2: Eckert MA, Orozco C, Xiao J, Javellana M, Lengyel E. The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment. Cancers (Basel). 2021 Jun 23;13(13):3136. doi: 10.3390/cancers13133136. PMID: 34201616; PMCID: PMC8268261.

3: Kuo MT, Huang YF, Chou CY, Chen HHW. Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy. Pharmaceuticals (Basel). 2021 Jun 8;14(6):549. doi: 10.3390/ph14060549. PMID: 34201235; PMCID: PMC8227247.

4: Oneda E, Abeni C, Zanotti L, Zaina E, Bighè S, Zaniboni A. Chemotherapy- induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention. World J Clin Oncol. 2021 Jun 24;12(6):458-467. doi: 10.5306/wjco.v12.i6.458. PMID: 34189069; PMCID: PMC8223716.

5: Zraik IM, Heß-Busch Y. Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen [Management of chemotherapy side effects and their long- term sequelae]. Urologe A. 2021 Jul;60(7):862-871. German. doi: 10.1007/s00120-021-01569-7. Epub 2021 Jun 29. PMID: 34185118.

6: Kast J, Dutta S, Upreti VV. Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors. Adv Ther. 2021 Jul;38(7):3712-3723. doi: 10.1007/s12325-021-01809-4. Epub 2021 Jun 18. PMID: 34152568.

7: Jackisch C, Cortazar P, Geyer CE Jr, Gianni L, Gligorov J, Machackova Z, Perez EA, Schneeweiss A, Tolaney SM, Untch M, Wardley A, Piccart M. Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. Cancer Treat Rev. 2021 May 20;99:102229. doi: 10.1016/j.ctrv.2021.102229. Epub ahead of print. PMID: 34139476.

8: Boztepe T, Castro GR, León IE. Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs. Int J Pharm. 2021 Jun 9;605:120788. doi: 10.1016/j.ijpharm.2021.120788. Epub ahead of print. PMID: 34116182.

9: Lv P, Man S, Xie L, Ma L, Gao W. Pathogenesis and therapeutic strategy in platinum resistance lung cancer. Biochim Biophys Acta Rev Cancer. 2021 Jun 4;1876(1):188577. doi: 10.1016/j.bbcan.2021.188577. Epub ahead of print. PMID: 34098035.

10: Daniels AB, Patel SN, Milam RW, Kohanim S, Friedman DL, Koyama T. Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class-A Meta-Analysis. Cancers (Basel). 2021 May 6;13(9):2216. doi: 10.3390/cancers13092216. PMID: 34066325; PMCID: PMC8125212.

11: Cirri D, Bartoli F, Pratesi A, Baglini E, Barresi E, Marzo T. Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments. Biomedicines. 2021 May 4;9(5):504. doi: 10.3390/biomedicines9050504. PMID: 34064364; PMCID: PMC8147839.

12: Toboni MD, Crane EK, Brown J, Shushkevich A, Chiang S, Slomovitz BM, Levine DA, Dowdy SC, Klopp A, Powell MA, Thaker PH. Uterine carcinosarcomas: From pathology to practice. Gynecol Oncol. 2021 Jul;162(1):235-241. doi: 10.1016/j.ygyno.2021.05.003. Epub 2021 May 21. PMID: 34030871.

13: Brandl A, Prabhu A. Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens. J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S32-S44. doi: 10.21037/jgo-2020-04. PMID: 33968424; PMCID: PMC8100714.

14: Sun T, Tian L, Guo Y, Zheng Y, Ouyang L, Zhang X, Lai Y, Yang G. Anaplastic carcinoma showing rhabdoid features combined with ovarian mucinous borderline cystadenoma: a case report and literature review. J Int Med Res. 2021 May;49(5):3000605211013159. doi: 10.1177/03000605211013159. PMID: 33951981; PMCID: PMC8113938.

15: Wang J, Liu Y, Liu N, Gao M, Yuan H. Paraneoplastic immunoglobulin A nephropathy in a patient with lung adenocarcinoma: A case report and literature review. J Int Med Res. 2021 Apr;49(4):300060521996868. doi: 10.1177/0300060521996868. PMID: 33926295; PMCID: PMC8113932.

16: Jagieła J, Bartnicki P, Rysz J. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. Int J Mol Sci. 2021 Apr 28;22(9):4618. doi: 10.3390/ijms22094618. PMID: 33924827; PMCID: PMC8125622.

17: Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021 Apr 28. doi: 10.1038/s41571-021-00501-4. Epub ahead of print. PMID: 33911215.

18: Serkies K, Baczkowska-Waliszewska Z. Adjuvant vaginal cuff brachytherapy in surgically treated endometrial carcinoma patients - in view of the recent evidence. J Contemp Brachytherapy. 2021 Apr;13(2):221-230. doi: 10.5114/jcb.2021.105291. Epub 2021 Apr 14. PMID: 33897797; PMCID: PMC8060967.

19: Hirte H, Poon R, Yao X, May T, Ethier JL, Petz L, Speakman J, Elit L. Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Crit Rev Oncol Hematol. 2021 Jun;162:103324. doi: 10.1016/j.critrevonc.2021.103324. Epub 2021 Apr 20. PMID: 33862245.

20: Farias JPF, Rangel da Silva MHC, Jácome AA. Emerging and Experimental Agents for Anal Cancer: What is New? J Exp Pharmacol. 2021 Apr 9;13:433-440. doi: 10.2147/JEP.S262342. PMID: 33859504; PMCID: PMC8043794.